
    
      This is a multicenter, randomized and open â…¡b phase study assessing the efficacy and safety
      of Alflutinib at doses of 80 mg orally /once daily and 160 mg orally /once daily in patients
      with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) harboring acquired
      T790M mutation after EGFR-TKI treatment or primary T790M mutation.
    
  